Introduktion
The aim of this analysis is to shed light on the inclusion and fairness of transgender athletes competing at the elite level of sports.

Since the International Olympic Committee (IOC) revised its guidelines concerning feminizing hormone therapy in 2015, questions have arisen about whether transgender athletes may still maintain a biological strength advantage even after complying with the stipulated duration of feminizing hormone therapy.

In recent years, the participation of transgender individuals in elite sports has become a contentious issue, particularly when they achieve success.

This has sparked numerous debates regarding the perceived biological strength advantages of transgender athletes compared to their cisgender counterparts.

Utdrag
In 2015, The International Olympic Committee (IOC) initiated a significant overhaul of its guidelines. The revised guidelines stipulate that transgender athletes must officially declare their gender identity and maintain it for a minimum of four years.

In addition, they are required to maintain a testosterone level lower than 10 nanomoles per liter for at least one year leading up to the competition and consistently throughout their eligibility.

Athletes who transitioned from female to male are allowed to compete without any restrictions, as there is no substantial evidence of a biological strength advantage in this case.

As mentioned earlier, transgender individuals must undergo a minimum of two years of feminizing hormone therapy, as this duration is deemed necessary for the various physical changes associated with this process.

Feminizing hormone therapy involves the administration of specific medications to suppress testosterone production and introduce estrogen to align one's physical attributes with their gender identity.

It's worth noting that hormone therapy isn't solely employed for gender transition but is also used in treating variou shormone-dependent cancers.